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Introduction: One of the criticisms of rehabilitation techniques is their limited application to the patient’s daily
life. In the past, cinema has been used as a psychiatric rehabilitation tool, with the primary objective of
facilitating training in social abilities and communication. In this study, we consider the use of ﬁlm not only as
a clinical recovery tool but also as a novel cognitive recovery tool for additional rehabilitation not only for
communication and social abilities but also for all of the basic cognitive and social cognition processes.
Methods: In this randomized clinical trial, 48 patients with schizophrenia were assigned to an experimental or
control group. Both of the groups received treatment sessions that included viewing episodes of the television
series The Sopranos. Next, the experimental group participated in a structured cognitive training session that
featured questions and exercises based on the episodes. The control group participated in an idea-sharing
session (of the same duration and frequency) about what the group members saw in the episode.
Results: At the end of the treatment, both the positive and negative clinical symptoms of the experimental
group improved signiﬁcantly compared with the control group. However, this improvement was not
observed in basic or social cognitive functions.
Discussion: A brief intervention based on transforming the activities of daily life can be an effective tool for
psychiatric rehabilitation. However, the study’s current characteristics and sample did not produce beneﬁts in
cognitive parameters.
© 2015 Published by Elsevier Inc.1. Introduction
Patients with schizophrenia are characterized by the presence of
cognitive problems in their daily lives (Harvey and Bowie, 2005).
Their functioning in standard activities such as employment, living
independently, or maintaining normal social activity is very limited
(Harvey et al., 2010), and pharmacological treatments have little
effect on their cognitive and functional recovery. Consequently,
common attempts at intervention focus on cognitive remediation
and other psychiatric rehabilitation alternatives.
There is a line of investigation regarding cognition in schizophrenia
based on the development and implementation of evaluation tech-
niques designed to promote autonomic function in this group ofcog.2015.06.001.
to, Facultad de Psicología y
ao, España. Tel.: +34 94 413patients. In the same fashion that neuropsychological testing progresses
toward methods more concerned with daily life (Ruse et al., 2014),
cognitive remediation increasingly tends to introducemethods relating
to the patient’s real life. Traditionally, attempts to carry out cognitive
remediation relevant to the patient’s daily life have adopted a top-down
focus that has been criticized for its limitations (Jardri and Deneve,
2013). The primary difﬁculty of these approaches is that they neglect
training in basic cognitive functions (such as attention, language, and
memory), and as a result, the patient is not guaranteed sufﬁcient
recovery of those functions, which help in the successful execution of
superior, more complex processes. However, although bottom-up
approaches accomplish such training, they have a limited capacity to
compensate for daily acquisitions in the patient’s real life. Far frombeing
a dead end, this challenge has prompted authors to develop appropriate
methodologies that include thebest of eachapproachand targetmatters
that the patients can develop in a normalized life.
More than a century ago, the appearance of ﬁlm as a form of
artistic expression evolved together with the globalization of society,
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and a tool of cognitive, artistic, audiovisual, and social development
(Bordwell et al., 1997; Cook, 1981). According to Dudai (2012), the
historical success of cinema is due to its status as a unique art form
that integrates, exploits, and promotes the cognitive faculties of the
human brain: working memory (WM), the capacity to mentally travel
through time (MTT), and the capacity to travel through the emotions.
Based on this approach, the author proposes that ﬁlm may be studied
through neurocerebral and neurocognitive substrates. The ability to
follow and understand a movie requires, inter alia, visuospatial
capacity, phonological and multisensory competency, efforts in WM,
language, episodic memory, mental management of time that
sometimes ﬂows in a non-linear fashion, management of concentrat-
ed attention, management of temporo-spatial coordinates, and
management of social empathy with the characters (Dudai, 2012).
All of these cognitive capacities together, whether simple or more
complex, entail high cognitive demand and enable us to understand
why patients with cerebral lesions or problems make functional
complaints about difﬁculty following a movie.
In people’s lives, cinema represents an activity that incorporates
ﬁctional stories and contexts that are in some way close to an
individual’s realities through the representation of behavior and the
transmission of emotion (Bellour, 2009). Accordingly, a movie offers
an intermediate context in the gap between real life and ﬁction. Movie
showings have traditionally been used in psychiatric rehabilitation
contexts because of movies’ ability to effectively reproduce both real
situations and situations that are close to reality (Hasson et al., 2008a,
2008b). The results of some studies that have used ﬁlm in
rehabilitation report beneﬁts in clinical symptoms, state of mind,
and patients’ social abilities (Gelkopf et al., 2006).
Encouraged by these reported beneﬁts, a group from Madrid’s
Puerta del Hierro Hospital developed a structuredmethod of cognitive
remediation based upon ﬁctional cinema and the famous series The
Sopranos. This method is based on both ﬁlm analysis theory (Aumont
and Marie, 1988; Goliot-Lété and Vanoye, 2012) and the principle of
cognitive remediation (Penadés and Gastó, 2010; Roder and Medalia,
2010; Roberts and Penn, 2013).
Adopting this approach, our team designed a clinical trial using
ﬁlm to evaluate the effect of cognitive remediation in patients with
schizophrenia. This trial also used The Sopranos, which contains
structured, homogeneous episodes that enable an analysis of the
impact of this technique on basic cognition, social cognition, clinical
symptoms, and functionality. Our hypothesis is that the group that
watches the series, in conjunction with the structured analytic
techniques and cognitive training, will improve its general cognitive
capacity and functional autonomy with respect to the control group.
2. Method
2.1. Participants
Forty-eight hospitalized patients with schizophrenia were recruit-
ed from both the Refractory Psychosis Unit of the Alava Psychiatric
Hospital and the Puerta de Hierro University Hospital in Majada-
honda, Madrid (both in Spain) in a collaborative study with the
University of Deusto Psychology Department. The inclusion criteria
were the following: between 18 and 75 years of age and fulﬁlling the
diagnostic criteria of schizophrenia according to the American
Psychiatric Association’s Diagnostic and Statistical Manual
DSM-IV-TR. The exclusion criteria included an age of less than 18
years or more than 75 years, evidence of drug or alcohol abuse within
the previous 30 days, a currently outstanding episode of seasonal
affective disorder, previous history of signiﬁcant loss of consciousness,
mental retardation, history of a relevant neurological or medicalepisode, and participation in another clinical trial. Both groups
received the standard treatment, which includes individual case
management and medical reviews.
All of the patients were stable at the time of their participation in
the study and received pharmacological treatment during their
participation.
2.2. Approval of protocol, registration, and informed consent
All of the participants voluntarily agreed to participate and signed
the informed consent of the study. The study’s protocol was approved
by the University of Deusto’s Committee of Ethics and Research.
2.3. Measures of clinical, cognitive, and functional evaluation
Twelve days after entry, all of the patients were evaluated from a
clinical, cognitive, and functional point of view. The clinical evaluation
included the SCID-I semi-structured diagnostic interview for psycho-
sis: Spanish version (First et al., 1997), the Positive and Negative
Syndrome Scale (PANSS, Spanish version) (Peralta Martín and Cuesta
Zorita, 1994), the Scale to Assess Unawareness in Mental Disorder
(SUMD) (Amador et al., 1994), and the Clinical Global Impressions
Scale (CGI) (Guy, 1970).
The neuropsychological evaluation included the Trail-Making Test
Parts A and B (Reitan and Wolfson, 1985), BACS test (Keefe et al.,
2004), the Hopkins Verbal Learning and Memory test (HVLT) (Brandt
and Benedict, 2001), the Brief Visuospatial Memory Test-Revised
(BVMT-R) (Benedict et al., 1996); the Letters and Numbers test, the
WAIS-III mazes (Wechsler, 1997), and a verbal and phonological
ﬂuency test (Peña-Casanova, 1990). Each participant’s social cogni-
tion performance was objectively evaluated using the Mayer-Salo-
vey-Caruso Emotional Intelligence Test -MSCEIT (Mayer et al., 2002),
the Reading the Mind in the Eyes Test (Baron‐Cohen et al., 2001), the
Faux-Pas Recognition Test, the Internal, Personal, and Situational
Attributions Questionnaire (IPSAQ) (Kinderman and Bentall, 1996). In
this fashion, we obtained measurements of the four principal factors
that constitute social cognition: emotion perception, social percep-
tion, theory of mind, and attributional style. The total scores on the
WAIS-III Vocabulary subtests were taken as an estimation of the
participant’s premorbid intellectual performance.
Each patient’s functional level was evaluated according to the
score obtained on the Personal and Social Performance Scale (PSP)
(Garcia-Portilla et al., 2013).
2.4. Procedure
First, an analysis of statistical power was conducted to determine
the size of the sample based on previous studies of cognitive
remediation with the same group (Sánchez et al., 2013). A sample
of 40 subjects, 20 in each group, was sufﬁcient to obtain an effect size
of 0.88, which detects a difference in cognitive remediation and
clinical variables with 80% power and a 5% conﬁdence level.
The design of the study was a randomized trial. Recruitment of the
participantswas carried out between September of 2011 andMarch of
2014. Following admission to the study, a simple random assignment
(tossing a coin) was conducted to place each participant in either the
experimental (n = 28) or control (n = 22) group (see Fig. 1). The
post-treatment evaluation occurred at a maximum of one week after
each patient completed his or her participation in the groups. All of
the evaluators were blind to the experimental or control condition in
which they encountered the participants. For ethical reasons, all of the
participants in the control group were offered the opportunity to
participate in a group that received the experimental intervention
once the study was ﬁnished.
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By consensus, the ﬁrst season of the television series The Sopranoswas
selected from a set of possible television series due to its quality,
cognitive-affective content, display of interpersonal relationships, and
widespread public acceptance. The programwas implemented in a group
format using pencil-and-paper tasks. All of the participants received 26
one-hour and 45-minute sessions over a period of 13 weeks. Two weekly
sessions, each separated by 48 hours, were conducted. The structure of the
sessions, as alongwith thedesignof the treatment program,was craftedby
the Psychiatry Services team at the Puerta del Hierro Hospital in Madrid.
The experimental group (EG) received speciﬁc, guided training
based on a systematic analysis of the series. After viewing each
episode, a systematic discussion of the footage was held and the
worked scenes were projected again, this time including the
corrections viewed in the ﬁrst showing. The basis of this method is
inspired by ﬁlm analysis theory. Film analysis is an intellectual
exercise of fragmenting a movie into its most basic elements to
establish and break down the relationships among them.
In the control group (CG), each patient spoke about his or her
favorite scene. Afterwards, a group discussion occurred without any
typeof standardizedguidance from the therapist. Both theexperimental
and control group sessions had the same duration and frequency.
2.6. Statistical analysis
The normality of the data was examined using the Kolmogorov-
Smirnov test. The categorical data were analyzed using a chi-squareAssessed for E
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Fig. 1. Flow diagram following CONtest. The multivariate analysis of variance (MANOVA) repeated
measures analysis included the neuropsychological, clinical, and
functional test results obtained in the two evaluation times as an
intra-group factor, and the group type (experimental vs. control) was
included as an inter-group factor. The signiﬁcance level was
established at 0.05. All of the tests were bilateral. All of the statistical
analyses were conducted using version 21 of the Statistical Package
for the Social Sciences statistical program (SPSS).3. Results
3.1. Sociodemographic characteristics of the groups
The sociodemographic characteristics of the experimental (EG)
and control (CG) groups are shown in Table 1. The general sample was
a group of patients with chronic schizophrenia who had severe
symptomatology and a high number of hospitalizations. The differ-
ences between the groups were analyzed to ensure good randomi-
zation. We did not encounter signiﬁcant differences between the
groups in any of the sociodemographic variables analyzed. Both of the
groups were equivalent in age, sex, and premorbid adjustment. There
were also no signiﬁcant differences between the groups in clinical
characteristics such as age at the ﬁrst diagnosis of schizophrenia,
number of previous hospitalizations, or presence of diagnostic
subtypes. The average dose of antipsychotics (mg/day of chlorprom-
azine equivalents) was similar at the baseline (F = 0.54 and p =
0.61) and the end of the intervention (F = 3.83 and p = 0.06).ligibility (n = 58)
Excluded (n = 8)
Not meeting inclusion criteria (n = 3)
Declined to participate (n = 2)
Other reasons (n = 3)
Lost to follow-up (discharged before 
completion of the intervention) (n = 1)
Discontinued intervention (n = 0)
Allocated to control group (n = 22)
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Table 1
Distinguishing sociodemographics and diagnostics of the participants by group. Average (standard deviation).
Experimental group Control group Group differences p
Age (years) 35.93 (8.1) 32.52 (9.8) F = 1.735 0.194
Education (years) 9.23 (2.7) 10.24 (2.8) F = 2.17 0.146
Sex: n (%)
Men 20 (57.0%) 15 (71.4%) χ2 = 0.838 0.546
Women 7 (43%) 6 (28.6%)
Time of disease progression (days) 145,8 (92,3) 125,1 (91,) F = 0.598 0.,443
Number of previous hospitalizations 3.2 (2.3) 3.33 (3.2) F = 0.035 0.853
WAIS-III vocabulary 38,93 (6.01) 36,71 (8.6) F = 1.12 0.301
Premorbid adjustment (Cannon-Spoor) 49.64 (25.5) 46.75 (22.2) F = 0.30 0.582
Doses of psychiatric medication (converted to mg/day of chlorpromazine) 695.09 (362.6) 911.88 (922.9) F = 1.77 0.186
DSM-IV-TR: n (%)
Paranoid 29 (80.6%) 40 (77.9%) χ2 = 0.73 0.866
Disorganized 4 (11.1%) 3 (6.3%)
Residual 2 (5.6%) 3 (6.3%)
Unspeciﬁed 1 (2.8) 2 (4.2%)
Occupation: n (%)
Employed 3 (8.3%) 2 (4.2%) χ2 = 2.35 0.308
Unemployed 9 (25.0%) 7 (14.6%)
Disabled 24 (66.7%) 39 (81.3%)
Marital Status: n (%)
Single 33 (91.7%) 45 (93.8%) χ2 = 0.13 0.935
Married 1 (2.1%) 1 (2.8%)
Separated or divorced 2 (5.6%) 2 (4.2%)
Note. DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders 4th edition, Revised Text.
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Except for letters andnumbers, no statistically signiﬁcantdifferences
were found between the two groups in the pre-treatment evaluation in
any of the analyzed variables (see Tables 2 and 3). The pattern of
cognitive deterioration observed at baseline in both groups did not
change signiﬁcantly in either group after the intervention (see Table 2).
This absence of change was reﬂected in the results obtained from bothTable 2
Changes in basic cognition, social cognition, and functionality between baseline and post-tr
Average (SD) Di
Pr
Experimental group Control group F
PSPtotal Pre 52.67 (2.7) 55.00 (3.0) 0.4
Post 57.42 (2.9) 58.10 (3.2)
TMT-A T° Pre 50.08 (4.7) 43.67 (4.3) 0.9
Post 47.00 (5.1) 42.80 (4.7)
Bacs T° Pre 38.50 (1.9) 39.50 (2.1) 0.2
Post 42.46 (2.6) 41.25 (2.8)
HVLT total Pre 20.42 (1.1) 21.25 (1.1) 0.2
Post 22.83 (1.1) 22.00 (1.1)
BVLT total Pre 17.42 (1.7) 19.45 (1.7) 0.9
Post 17.83 (1.7) 19.50 (1.8)
Letters and numbers Pre 11.63 (0.5) 13.350 (0.6) 4.8
Post 11.21 (0.7) 12.70 (0.8)
Mazes Pre 11.04 (1.3) 12.15 (1.5) 0.8
Post 11.67 (1.4) 14.50 (1.5)
Verbal ﬂuency Pre 16.79 (0.7) 18.20 (0.8) 1.3
Post 18.46 (1.0) 18.95 (1.0)
MSCEIT Pre 86.91 (1.7) 84.57 (1.9) 0.4
Post 88.53 (2.5) 86.52 (2.7)
Mind reading Pre 21.29 (0.8) 19.10 (0.9) 3.8
Post 20.63 (0.9) 20.85 (0.8)
Faux-pas recognition Pre 29.50 (3.3) 32.35 (3.6) 0.1
Post 33.13 (3.9) 37.75 (4.3)
Note. SD = Standard; PSPtotal = Overall score in the Personal and Social Performance test
BacsT° = Total time in seconds to complete BACS; HVLT total = Total number of words af
total = Total number of drawings after three training period trials of the Brief Visual Learni
Numbers subtest of WAIS-III; Mazes = Total time in seconds of the maze subtest of WAIS-III
on the Mayer-Salovey-Caruso Emotional Intelligence Test; Mind reading = Total score on th
recognition test.basic and social cognition. The functional performance analyzed
through results obtained in the personal and social performance (PSP)
scale did not show signiﬁcant variations before or after the intervention
in either of the two groups (see Table 2 for more details).
However, the experimental group showed a signiﬁcant reduction of
clinical symptoms measured by the PANSS in comparison with the
control group. This change was objectively seen in positive (p b 0.005),
negative (p b 0.000), and general symptoms (p b 0.000) (see Table 3).eatment in the experimental and control groups.
fferences
e-treatment
Primary effect
Group
Primary effect
Time
Interaction
group × time
p F p F P F p
9 0.484 0.15 0.71 8.74 0.005 0.39 0.538
5 0.334 0.11 0.75 3.79 0.059 0.17 0.686
9 0.590 0.00 0.97 4.56 0.039 0.68 0.413
7 0.601 0.14 0.71 6.18 0.017 1.71 0.198
7 0.328 0.39 0.54 0.11 0.744 0.04 0.841
5 0.033 3.61 0.06 1.47 0.232 0.07 0.792
4 0.363 1.02 0.32 7.21 0.010 2.43 0.127
4 0.252 0.73 0.40 3.49 0.068 0.50 0.482
6 0.497 0.60 0.44 1.45 0.235 0.01 0.914
5 0.056 0.89 0.35 0.72 0.400 3.60 0.015
4 0.703 0.58 0.45 4.64 0.037 0.18 0.004
(PSP); TMT-AT° = Total time in seconds to complete part A of the Trail-Making test;
ter three training period trials of the Hopkins Verbal Learning and Memory Test; BVLT
ng and Memory test; Letters and Numbers = Total number of items in the Letters and
; Verbal ﬂuency = Total number of words evoked in one minute; MSCEIT = Total score
e Reading the Mind in the Eyes test; Faux pas recognition = Total score in the faux-pas
Table 3
Changes in clinical symptoms between baseline and post-treatment in the experimental and control groups.
Average (SD) Differences
Pre-treatment
Primary effect
Group
Primary effect
Time
Interaction
group × time
Experimental group Control group F p F p F P F p
Positive symptoms (PANSS) Pre 15.17 (1.2) 12.85 (1.3) 1.81 0.186 0.40 0.84 8.80 0.005 6.71 0.013
Post 10.75 (0.9) 12.63 (0.9)
Negative symptoms (PANSS) Pre 21.54 (1.6) 17.91 (1.7) 2.39 0.129 0.22 0.64 28.86 0.000 12.9 0.001
Post 15.00 (1.4) 16.65 (1.5)
General psychopathology (PANSS) Pre 37.63 (2.8) 32.35 (3.1) 1.56 0.217 0.32 0.56 15.74 b0.001 6.39 0.413
Post 28.83 (1.8) 30.40 (2.0)
CGI Pre 4.10 (0.83) 3.87 (0.92) 2.39 0.131 0.20 0.66 13.85 0.001 9.75 0.198
Post 3.33 (0.73) 3.80 (1.01)
PANSS = Positive and Negative Syndrome Scale; CGI = Clinical General Impression Scale.
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The design of the intervention program with cinema used in this
sample of patients with schizophrenia is based both on principles of
ﬁlm analysis theory and on cognitive remediation, which intends to
improve the clinical and cognitive situation of the population to which
it is applied. Following its intensive use in our sample of participants,
we did not observe any signiﬁcant change in the realm of cognition,
the participants’more basic processes (attention, language, memory),
or in theirmore complex processes of social cognition. Despite the fact
that the structure, objective, and content of the sessions were mainly
directed towards the search for remediation of the selected sample’s
cognitive deﬁcits, it seems that themechanisms that wouldmake such
a recovery effective are not reﬂected in the employed method.
That notwithstanding, the practiced intervention with the exper-
imental group did lead to an important change in the gravity of their
clinical symptomatology. The reduction in clinical symptoms (positive
and negative) was much higher than that observed in the control
group, even though the rest of the interventions were ordinary. This
fact is especially apparent in the negative symptoms, which are
habitually more resistant to recovery through other therapeutic
measures. Given that both groups shared the remainder of the
variables during the clinical trial, we cannot attribute the symptom
recovery in the experimental group to other factors such as the hours
of attention received, the qualiﬁcation of the therapists who
intervened, or the type of pharmacological treatment used. In
accordance with what other authors have identiﬁed in schizophrenia,
it is more likely that the combination of pharmacological and
psychological treatments together with the experimental interven-
tion reinforced the symptomatological recovery (Fusar-Poli et al.,
2014). In previous clinical trials, our group tested neuropsychological
rehabilitation methods demonstrating combined efﬁcacy in cognition
and negative symptomatology (Sánchez et al., 2013). In the
methodology with the Rehacop program, however, the reinforcement
principles of bottom-up mechanisms were applied. In this clinical
experiment, only top-down mechanisms were used. Further studies
that directly compare the efﬁcacy of these two methodologies in the
processes of cognitive recovery in schizophrenia are necessary.
Although some clinical groups claim the need for personalized
treatment of the negative symptoms of patients with schizophrenia
(Foussias et al., 2014), we have already used treatments applied in a
group setting that seem efﬁcient in reducing negative symptoms.
Despite this study’s presentation of promising data in terms of
clinical changes exhibited by the patients, it also presents some
limitations. The ﬁrst is that this study lacks measurement scales for
quality of life and other functional scales additional to the PSP. Future
studies should measure the effect of this type of intervention on the
aforementioned factors. The second limitation is that the measure-ment of negative symptoms was conducted with the traditional
PANSS, whereas currently, and subsequent to the design of this study,
there are more appropriate clinical scales available with less
limitation for measurement of the same attributes.
The clinical proﬁle of the patients requiresmention. The severity of
the proﬁle has not been a factor in preventing improvement in clinical
symptoms, but it is a factor in ﬁnding positive changes in cognition
and functionality. Finally, a long-term, longitudinal follow-up would
be convenient to analyze whether the observed clinical changes
persist through time.
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